TATA健康(01255.HK)預計年度虧損1.5億至1.7億港元
格隆匯3月19日丨TATA健康(01255.HK)公吿,公司預計截至2020年12月31日止年度錄得歸屬母公司淨虧損約1.5億港元至約1.7億港元。該年度的淨虧損預期主要是由於(i)受到2019冠狀病毒病疫情影響導致訪港旅客持續減少以及消費者在全球經濟下滑狀況下更為審慎,這使得分別構成集團主要營收來源的鞋類及保健業務均受到嚴重衝擊。預期於該年度集團總體銷售收入與去年同期相比下滑約50%至60%;及(ii)集團於該年度將錄得增加了資產減值損失,包括但不限於鞋類產品存貨撥備、使用權資產及無形資產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.